Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Investigation on Adhesion Control Standards and Skin Adverse Effects of Skin Attached Formulations

파스제의 점착력 관리기준 및 피부 부작용 조사연구

  • Kim, Ji Yeon (Department of Food and Drug, Chosun University Graduate School) ;
  • Kim, Kwang Joon (College of Pharmacy, Chosun University) ;
  • Park, Sang-Wook (Department of Food and Drug, Chosun University Graduate School) ;
  • Bang, Joon Seok (Graduate School of Clinical Pharmacy, Sookmyung Women's University) ;
  • Lee, Wonjae (Department of Food and Drug, Chosun University Graduate School)
  • 김지연 (조선대학교 대학원 식품의약학과) ;
  • 김광준 (조선대학교 약학대학 약학과) ;
  • 박상욱 (조선대학교 대학원 식품의약학과) ;
  • 방준석 (숙명여자대학교 임상약학대학원) ;
  • 이원재 (조선대학교 대학원 식품의약학과)
  • Received : 2014.07.02
  • Accepted : 2014.08.21
  • Published : 2014.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This paper was aimed to investigate the adhesion control standards of pain relieving patch (PRP) drugs and to survey it's adverse effects on the skin of patients for safe use of PRP drugs. Methods: In this study, the related documents of PRP drugs of Korea pharmacopoeia (KP), United States pharmacopoeia (USP), Japanese Pharmacopoeia (JP), European pharmacopoeia (EP), and information web sites of the Ministry of Food and Drug Safety (MFDS) were surveyed. Also, the past and current labeling of PRP drugs marketed in the pharmacy was investigated and compared. Results: In KP and JP, the lower limit standard for PRP's adhesion control is established, but the upper limit standard is not designated. In USP and EP, neither the lower nor upper limit standard is established. The main reasons of skin adverse effects are considered as inherent adverse reactions of the applied drugs for PRP. Another reason is involved in patient's medication mistakes related to PRP's adhesion control, respiratory depression of skin according to physical skin closure, and microbial growth, etc. Conclusion: For safe use of PRP drugs, we proposed ensured guidelines like additional instructions of pharmacist's prescription and detailed labeling systems for usage of PRP drugs applied on skin.

Keywords

References

  1. Notice #2014-46, KMFDS 'Korean Pharmacopoeia: General Formulation' http://www. mfds.go.kr/index.do?x=0&searchkey =title:contents&mid=1013&searchword=대한민국약전&y= 0&division=&pageNo=1&seq=6313&cmd=v (Accessed on February 12, 2014).
  2. Transdermal formulation, Choi HK, Shinil Books, Seoul, Korea, 1999.
  3. Report information by Korea Customer Agency http:// www.kca.go.kr/brd/m_32/view.do?seq=1361&multi_itm_seq=, (Accessed on November 9, 2012).
  4. Korea National Institute of Food and Drug Safety Evaluation, "Research on establishing of guidelines for evaluating the effectiveness of drug safety", 2011.
  5. Japanese Pharmacopoeia $15^{th}$ edition, Ministry of Health, 2010.
  6. United States Pharmacopoeia $34^{th}$ edition, USP Convention, 2011.
  7. European Pharmacopoeia 7.0, European Directorate for the Quality of Medicines & Health Care, 2011.
  8. EZdrug, Korea Ministry of Food and Drug Safety. http:// ezdrug.mfds.go.kr (Accessed on June, 2014)
  9. Notice #2014-46, KMFDS 'Korean Pharmacopoeia: Individual Monograph'. Internet site: http://www.mfds.go.kr/ index.do?x=0&searchkey=title:contents&mid=1013&searchwo rd= 대한민국약전&y=0&division=&pageNo=1&seq=6313 &cmd=v (Accessed on February 12, 2014).
  10. Notice #2013-235, KMFD 'Criteria for non-formulary drugs excluding Korean Pharmacopoeia'. Internet site: http://www. mfds.go.kr/index.do?x=0&searchkey= title:contents&mid =1013&searchword=대한민국약전외&y= 0&division=&page No=1&seq=6312&cmd=v (Accessed on November 21, 2013).
  11. Notice #2014-58, KMFD 'Regulations for marketing and sales, report, review of authorized medications'. Internet site: http://www.mfds.go.kr/index.do?x=0&searchkey=title: contents&mid=1013&searchword= 의약품의 품목&y=0& division=&pageNo=1&seq=7773&cmd=v (Accessed on February 12, 2014).
  12. Notice #2014-77, KMFD 'Standards and test methods on the quasi-drugs'. Internet site: http://www.mfds.go.kr/ index.do?x=0&searchkey=title:contents&mid=1013&search word= 의약외품 &y=0&division=&pageNo=1&seq=7737 &cmd=v (Accessed on February 12, 2014).
  13. Drug approval and licensing procedures in Japan 2010.
  14. Prez-Caldern R, Gonzalo-Garijo MA, Rodrguez-Nevado I. Generalized allergic contact dermatitis from nitroglycerin in transdermal therapeutic system. Contact Dermatitis 2002;46(5):303. https://doi.org/10.1034/j.1600-0536.2002.460513.x
  15. Alfaya T, Mur Gimeno P, Iglesias AM, et al. Allergic contact dermatitis caused by an ethinylestradiolnorelgestromin transdermal therapeutic system. Contact Dermatitis 2011;64(4):237-44. https://doi.org/10.1111/j.1600-0536.2010.01848.x
  16. FDA safety page, drug topics. April 1, 2002. Lee M and Phillips J.
  17. Tokumura F, Ohyama K, Fujisawa H, et al. Conformability and irritancy of adhesive tapes on the skin. Contact Dermatitis 1997;37(4):173-78. https://doi.org/10.1111/j.1600-0536.1997.tb00191.x
  18. Wokovich AM, Prodduturi S, Doub WH, et al. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm 2006;64(1):1-8. https://doi.org/10.1016/j.ejpb.2006.03.009
  19. Cilurzo F, Gennari CG, Minghetti P. Adhesive properties: a critical issue in trans- dermal patch development. Expert opin drug deliv 2012;9(1):33-45. https://doi.org/10.1517/17425247.2012.637107
  20. Satas D. Handbook of Pressure Sensitive Adhesive Technology, 3rd ed. Rhode Island: Satas & Associates, 1999;36-61.
  21. Korea Pharmaceutical Information Center (Accessible at http://www.health.kr)
  22. Druginfo, Drug Information Organization in Korea (Accessible at http://www.druginfo.co.kr)